Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorFerrándiz-Pulido, C. (C.)-
dc.creatorGómez-Tomás, A. (A.)-
dc.creatorLlombart, B. (B.)-
dc.creatorMendoza, D. (D.)-
dc.creatorMarcoval, J. (J.)-
dc.creatorPiaserico, S. (S.)-
dc.creatorBaykal, C. (C.)-
dc.creatorBouwes-Bavinck, J.N. (J.N.)-
dc.creatorRacz, E. (E.)-
dc.creatorKanitakis, J. (J.)-
dc.creatorHarwood, C.A. (C.A.)-
dc.creatorCetkovska, P. (P.)-
dc.creatorGeusau, A. (A.)-
dc.creatorDel-Marmol, V. (V.)-
dc.creatorMasferrer, E. (E.)-
dc.creatorOrte-Cano, C. (C.)-
dc.creatorRicar, J. (J.)-
dc.creatorde-Oliveira, W.R. (W.R.)-
dc.creatorSalido-Vallejo, R. (Rafael)-
dc.creatorDucroux, E. (E.)-
dc.creatorGkini, M.A. (M.A.)-
dc.creatorLópez-Guerrero, J.A. (José Antonio)-
dc.creatorKutzner, H. (H.)-
dc.creatorKempf, W. (W.)-
dc.creatorSeckin, D. (D.)-
dc.identifier.citationFerrándiz-Pulido, C.; Gómez-Tomás, A.; Llombart, B.; et al. "Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study". Journal of the European Academy of Dermatology and Venereology. 36 (11), 2022, 1991 - 2001es
dc.description.abstractBackground The proportion of Merkel cell carcinomas (MCCs) in solid-organ transplant recipients (SOTR) harbouring Merkel cell polyomavirus (MCPyV) is unknown, as are factors affecting their outcomes. Objective To describe clinicopathological features of MCC in SOTR, investigate the tumoral MCPyV-status and identify factors associated with tumour outcomes. Methods Retrospective, international, cohort-study. MCPyV-status was investigated by immunohistochemistry and polymerase chain reaction. Results A total of 30 SOTR and 44 consecutive immunocompetent patients with MCC were enrolled. SOTR were younger at diagnosis (69 vs. 78 years, P < 0.001). Thirty-three percent of SOTR MCCs were MCPyV-positive vs. 91% of immunocompetent MCCs (P = 0.001). Solid-organ transplantation was associated with an increased cumulative incidence of progression (SHR: 3.35 [1.57-7.14], P = 0.002), MCC-specific mortality (SHR: 2.55 [1.07-6.06], P = 0.034) and overall mortality (HR: 3.26 [1.54-6.9], P = 0.002). MCPyV-positivity and switching to an mTOR inhibitor (mTORi) after MCC diagnosis were associated with an increased incidence of progression (SHR: 4.3 [1.5-13], P = 0.008 and SHR: 3.6 [1.1-12], P = 0.032 respectively) in SOTR. Limitations Retrospective design and heterogeneity of SOTR cohort. Conclusions MCPyV appears to play a less prominent role in the aetiopathogenesis of MCC in SOTR. SOTR have a worse prognosis than their immunocompetent counterparts and switching to an mTORi after the diagnosis of MCC does not improve progression.-
dc.titleClinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study-
dc.description.noteThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License-
dadun.citation.publicationNameJournal of the European Academy of Dermatology and Venereology-

Ficheros en este ítem:
Vista previa
829.22 kB
Adobe PDF

Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.